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Abstract
Patients with metastatic, platinum-resistant urothelial carcinoma (PRUC) have no Food and Drug Administratione
approved therapies. The response rates to second-line chemotherapy have generally been < 20%, with a median
overall survival of < 1 year. We report our experience with 6 heavily pretreated patients with advanced PRUC
(ClinicalTrials.gov identiﬁer NCT01631552) with the novel antibodyedrug conjugate, sacituzumab govitecan (IMMU-
132). This antibodyedrug conjugate comprises the active metabolite of irinotecan, SN-38, conjugated to an anti-Trop-2
antibody. Trop-2 is widely expressed in  83% of urothelial carcinomas. Of the 6 patients, 3 had a clinically signiﬁcant
response (progression-free survival, 6.7 to 8.2 months; overall survival, 7.5þ to 11.4þmonths). Sacituzumab govitecan was
well tolerated. Because of these results, a phase II trial has been initiated. The present report highlights the promise of
antibodyedrug conjugates, such as sacituzumab govitecan, as a novel therapeutic strategy for the treatment of PRUC.
Clinical Genitourinary Cancer, Vol. 14, No. 1, e75-9 ª 2016 The Authors. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Urothelial bladder carcinoma (UC) is the sixth most frequent
cancer.1,2 Cisplatin-based combination chemotherapy is the only
known treatment that has demonstrated a survival beneﬁt for pa-
tients with advanced disease.3,4 However, only a small subset will
attain long-term survival. For those participating in clinical trials,
the median overall survival has been 15 months and the 5-year
survival has been only 15%.5 After progression within 6 to 12
months of platinum-based chemotherapy (platinum-resistant uro-
thelial carcinoma [PRUC]), whether delivered in the perioperative
or advanced setting, survival has been only 4 to 9 months for
subjects eligible for enrollment in clinical trials. No second-line
chemotherapy agents have been approved in the United States,1Division of Hematology and Medical Oncology, Weill-Cornell Medical College, New
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http://dx.doi.org/10.1016/j.clgc.2015.10.002and only vinﬂunine is available in Europe.6 Developing effective
second-line therapies for advanced urothelial cancer represents an
important unmet medical need.7
Antibodyedrug conjugates (ADCs) targeting cell-surface antigens
represent an attractive therapeutic strategy for chemotherapy-refractory
tumors, including PRUC.8 Sacituzumab govitecan (IMMU-132) is a
second-generation ADC comprising a humanized anti-Trop-2 mono-
clonal antibody (hRS7) conjugated with the active metabolite of irino-
tecan, SN-38.9 It has demonstrated acceptable toxicity and encouraging
therapeutic activity in several solid tumors, both preclinically and clini-
cally,8,10 and is a rational choice for targeting UC. Trop-2 (TACSTD2)
protein is known to be expressed in normal urothelium11 and in  83%
of urothelial carcinomas.12 A phase II clinical trial with irinotecan in
patients with PRUC demonstrated an overall response rate of only 5%
(95% conﬁdence interval, 1%-17%), including a complete response
lasting 33 months and overall survival of 5.4 months.13 Irinotecan has
also been used in combination with other drugs.14
As part of an extended trial evaluating sacituzumab govitecan
(ClinicalTrials.gov identiﬁer, NCT01631552), we initially studied
6 patients with PRUC, 3 of whom achieved clinically signiﬁcant
responses. The present brief communication describes this clinicalClinical Genitourinary Cancer February 2016 - e75
Table 1 Baseline Characteristics and Clinical Outcomes
Pt. No Sex Age (Years)
Primary UC
Site
Metastatic
Sites
Previous
Treatment Hb (g/dL) LDH (IU/L)
Albumin (g/
dL)
Sacituzum b Govitecan
Best
Response
(%) PFS (mo) OS (mo)
Dose (mg/
kg) Cycles (n)
1 M 42 Bladder Bone Gemcitabine þ
carboplatin
13 134 3.8 12 4 PD (30) 1.5 10.8
Gemcitabine þ
cisplatin
Docetaxel
2 M 80 Renal pelvis Liver, lung,
mediastinal
lymph nodes
Gemcitabine þ
carboplatin
12.7 210 4 10 6 PD (30) 1.9 1.9þ
3 M 71 Bladder Pelvic, para-
aortic, RPLNs
Paclitaxel,
ifosfamide,
cisplatin
11.1 218 3.9 8 4 PD (12) 1.8 1.8þ
Docetaxel
4 M 66 Renal pelvis Lung, para-aortic
lymph nodes,
psoas muscle
Gemcitabine þ
cisplatin
9.6 148 3.6 8 13 SD (28) 6.7 11.4þ
5 M 74 Bladder SCV,
mediastinal,
RPLNs
BCG 13.5 156 4.4 11 12þ PR (33) 7.5þ 7.5þ
Gemcitabine þ
cisplatin
Investigational
(DN24-02)
6 M 75 Ureter Liver, lung, pelvic
lymph nodes,
peritoneum
Gemcitabine þ
cisplatin
(adjuvant)
9.3 187 2.6 8 25 PR (38) 8.2 10.5
Gemcitabine þ
carboplatin
Docetaxel þ
icrucumab
Abbreviations: BCG ¼ bacille Calmette-Guérin; Hb ¼ hemoglobin; LDH ¼ lactate dehydrogenase; M ¼ male; OS ¼ overall survival; PD ¼ progressive disease; PFS ¼ progression-free surviv ; PR ¼ partial response; Pt. No. ¼ patient number; RECIST 1.1 ¼ Response
Evaluation Criteria in Solid Tumors, version 1.1; RPLNs ¼ retroperitoneal lymph nodes; SCV ¼ supraclavicular; SD ¼ stable disease; UC ¼ urothelial carcinoma.
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Figure 1 Waterfall Plot of Best Responses in 6 Patients With
Urothelial Carcinoma Treated With Sacituzumab
Govitecan
Abbreviations: PD ¼ progressive disease; PR ¼ partial response; Pt ¼ patient;
RECIST ¼ Response Evaluation Criteria in Solid Tumors; SD ¼ stable disease.
Bishoy Faltas et alexperience, which suggests that this ADC is an attractive candidate
for further evaluation as a treatment of PRUC.
Materials and Methods
Patients were eligible for the trial if they had advanced PRUC, an
Eastern Cooperative Oncology Group performance status of 0 to 1,
and intact organ function.10 All the patients provided informed
consent. The patients were recruited under protocol 1212013347,
which was approved by the Weill-Cornell Medical College insti-
tutional review board, and protocol 13.029.03, approved by the UF
Health Cancer Center at Orlando Health. All experimental pro-
cedures were performed in accordance with approved guidelines.
Sacituzumab govitecan was administered intravenously on days 1
and 8 of 21-day cycles that were repeated until dose-limiting
toxicity or progression developed. Response was assessed using the
Response Evaluation Criteria in Solid Tumors, version 1.1. When
available, immunohistochemical staining of archival tumor biopsy
specimens obtained from treated patients was performed as
described previously.10
Results
The median patient age was 72.5 years (range, 42-80 years). All
patients had metastatic disease and had been previously treated with
platinum-containing regimens and other lines of therapy (median
number of previous therapies, 3; Table 1). Of the 6 patients, 5 were
in the poor or intermediate-risk groups according to the prognostic
model for patients with UC receiving salvage systemic therapy.15 All
6 patients with PRUC were available for the response assessment.
Two achieved a partial response, with the best responder having a
38% reduction in target lesions, including liver metastases
(Figure 1). One patient had stable disease, with a 28% reduction in
target lesions, and 3 patients had progressive disease, including 1
patient who was considered to have progressive disease using theResponse Evaluation Criteria in Solid Tumors, version 1.1, because
of a new lesion, despite a 12% reduction in his target lesions with
treatment (Table 1). For the 3 patients with a clinically signiﬁcant
response, the progression-free survival was 6.7 to 8.2 months and
overall survival was 7.5þ to 11.4þ months. Sacituzumab govitecan
was generally well tolerated; 2 patients experienced grade 3 toxicities
(ﬂank pain and bacteremia). No grade 4 nonhematologic toxicities
were observed. Immunohistochemical analysis of archival PRUC
tumor tissue from patients treated with sacituzumab govitecan
showed signiﬁcant cell surface expression of Trop-2 protein
(Figure 2).
Discussion
Although the vinca alkaloid vinﬂunine is available in Europe
because of results from a phase III trial comparing it with the best
supportive care in the second-line setting, its efﬁcacy was marginal,
with no overall survival advantage.6 The overall response rate for
patients treated with second-line therapy, such as vinﬂunine or
other agents, including the taxanes and pemetrexed, has usually
been < 20%, with a median overall survival of only 4 to 9
months.6,16,17 A recently presented positive phase II randomized trial
of docetaxel with or without ramucirumab or icrucumab demon-
strated a response rate of 5% and a progression-free survival of 10.4
weeks in the docetaxel-alone control arm.18 A large institutional review
of the frequently prescribed second-line agent, pemetrexed, showed an
objective response rate of 5% (95% conﬁdence interval, 1%-9%) and
a median progression-free survival of 2.4 months.19 Thus, at present,
patients with PRUC have limited therapeutic options.7
In this ﬁrst group of patients with PRUC enrolled in the phase I/
II trial, sacituzumab govitecan showed an early signal of signiﬁcant
clinical activity in this heavily pretreated cohort. As previously
observed in UC cell lines and patient-derived PRUC tumors, we
detected high levels of Trop-2 protein expression in tumor biopsies
from patients treated with sacituzumab govitecan. Our sample size
did not permit a correlation between the Trop-2 expression levels
and clinical response. However, the activity observed in this small
subset of patients with PRUC, with good overall tolerability, is
consistent with preclinical results indicating that the ADC selec-
tively delivers a signiﬁcant proportion of the potent drug to the
tumor cells rather than to normal cells.20 Because of these promising
observations, we have initiated a multicenter phase II expansion
cohort with a target enrollment of 50 patients with PRUC designed
to exclude an objective response rate of < 15% to warrant further
examination in a randomized study.
Conclusion
The present report highlights the promise of targeted therapy
with an ADC, sacituzumab govitecan, as a novel therapeutic strategy
for the treatment of PRUC.
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Figure 2 (A) Assessment of Target Lesions on Computed Tomography (CT) Scans Using Response Evaluation Criteria in Solid Tumors,
Version 1.1, in Patient (Pt) 6 Before and After Sacituzumab Govitecan Treatment. Patient 6 Initially Presented With 4 Target
Lesions (2 Liver, 1 Sigmoid Colon, 1 Peritoneum of Pelvis), With a Sum of the Largest Diameters of 138 mm. Additional
Nontarget Lesions Were Present in the Liver and Lymph Node in the Pelvis. Treatment Was Initiated at a Dose Level of 8 mg/
kg February 27, 2014. White Arrows Highlight Target Lesions 1-3 in Axial Slices Obtained at Baseline. Axial Slices of the
Same Region 6 Months Later (August 22, 2014) After 9 Cycles of Sacituzumab Govitecan Treatment Demonstrated Reduction
in Sum Diameter of Target Lesions to 86 mm (L38%) and Stable Disease in Nontarget Lesions. (B) Expression of Trop-2
(TACSTD2) Obtained From Three Patients With Urothelial Carcinoma Treated With Sacituzumab Govitecan (Patients 3, 4, and
6). Control Slides Were Incubated With Normal Goat IgG. Corresponding Sections Incubated With Goat Anti-Trop-2 Antibody
Demonstrated Strong Trop-2 Expression. Enlarged Inset of Trop-2-expressing Cells (Patient 6) Demonstrated Localization of
Trop-2 to Cell Membranes. Scale Bars [ 0.1 mm
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